Encorafenib and Binimetinib: First Global Approvals
Encorafenib and Binimetinib: First Global Approvals
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Encorafenib (Braftovi™), a BRAF inhibitor, and binimetinib (Mektovi
®
), a MEK inhibitor, are two orally bioavailable drugs developed by Array BioPharma. In June 2018 they each received their first global approval, in the USA, for use in combination, for patients with unresectable or metastatic melanoma with a BRAF
V600E
or
-V600K
Alternative Titles
Full title
Encorafenib and Binimetinib: First Global Approvals
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2089855014
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2089855014
Other Identifiers
ISSN
0012-6667
E-ISSN
1179-1950
DOI
10.1007/s40265-018-0963-x
